Summary
Elevance Health, Inc. (formerly Anthem, Inc.) filed an 8-K on December 7, 2017, primarily announcing two significant corporate actions. Firstly, the Board of Directors elected Antonio F. Neri as an independent director, effective immediately, who will also serve on the Audit Committee. His appointment is in accordance with the company's standard compensation program for non-employee directors. Secondly, and of greater financial consequence for investors, the Board approved a substantial increase of $5 billion to the company's share repurchase authorization, bringing the total available for repurchases to approximately $7.3 billion. The company intends to execute this expanded authorization over multiple years, contingent on market and industry conditions, signaling a strong commitment to returning capital to shareholders.
Key Highlights
- 1Appointment of Antonio F. Neri as an independent director to the Board and Audit Committee.
- 2Significant increase of $5 billion to the company's share repurchase authorization.
- 3Total available share repurchase authorization now stands at approximately $7.3 billion.
- 4The company plans to utilize the increased repurchase authorization over a multi-year period.
- 5The repurchase program is subject to market and industry conditions.
- 6The filing was made on December 7, 2017, related to events on December 5-6, 2017.
- 7Antonio F. Neri has no disclosed conflicts of interest or material interest in transactions requiring disclosure.